Phase 2 N=36 RAD001 and Bicalutamide for Androgen Independent Prostate Cancer
Prostate Cancer
Primary: Overall Response Rate — 6 percentage of patients
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=35 Maximal Suppression of the Androgen Axis in Clinically Localized Prostate Cancer
Cancer · Prostate Neoplasms
Primary: Prostate Tissue DHT — 0.03; 0.06; 0.03 ng/g
Phase 2 N=31 Quinacrine Treatment in Patients With Androgen-Independent Prostate Cancer
Prostatic Cancer
Primary: Efficacy of Quinacrine, Based on Prostate Specific Antigen (PSA) Response in Patients With Androgen-independent Metastatic Prostate Cancer — 1 Participants
Phase 2 N=39 Study of Taxotere and Doxil to Treat Advanced Androgen-Independent Prostate Cancer
Prostate Cancer
Primary: Maximum Tolerated Dose and Toxicity Profile
Phase 3 N=1,224 Aflibercept in Combination With Docetaxel in Metastatic Androgen Independent Prostate Cancer
Prostatic Neoplasms · Neoplasm Metastasis
Primary: Overall Survival Time — 21.22; 22.14 months — p=0.3802
Phase 2 N=29 Single Agent Erlotinib in Chemotherapy-naive Androgen Independent Prostate Cancer
Prostate Cancer
Primary: Overall Clinical Benefit of Tarceva in CRPC. — 36 percentage of pts w/clinical benefit
Phase 2 N=90 The Role of Highly Selective Androgen Receptor (AR) Targeted Therapy in Men With Biochemically Relapsed Hormone Sensitive Prostate Cancer
Prostate Cancer
Primary: Change From Baseline in Functional Assessment of Cancer Therapy - Prostate (FACT-P) Total Score at 12 Months — -8.04; -6.60; -9.42 Units on a scale
Phase 2 N=18 Sorafenib and Docetaxel in Patients With Prostate Cancer That Did Not Respond to Previous Hormone Therapy
Prostate Cancer
Primary: Prostate Specific Antigen (PSA) Response Rate — 6 Participants
Phase 2 N=10 Ipilimumab in Combination With Androgen Suppression Therapy in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
Adenocarcinoma of the Prostate · Hormone-resistant Prostate Cancer · Recurrent Prostate Cancer
Primary: Percentage of Patients Who Achieve an Undetectable PSA (=< 0.2 ng/ml) — 0.0 percentage of patients
Phase 2 N=22 Sorafenib to Overcome Resistance to Systemic Chemotherapy in Androgen-independent Prostate Cancer
Prostate Cancer
Primary: Percentage of Patients Needing a Dose Reduction. — 71 percentage of participants
Phase 2 N=10 Fulvestrant in Hormone Refractory Prostate Cancer
Prostatic Neoplasms · Prostate Cancer
Primary: PSA Reduction ≥ 50% — 0 participants
Phase 2 N=45 Radiation and Androgen Ablation for Prostate Cancer
Adenocarcinoma of the Prostate
Primary: Biochemical Failure Free-rate (BFFR) Associated With the Combined Hypofractionated Dose Regimen and Androgen Deprivation Therapy (ADT). — 0 progression events
Phase 2 N=62 Cabozantinib and Androgen Ablation in Patients With Androgen-Dependent Metastatic Prostate Cancer
Prostate Cancer
Primary: Progression Free Survival — 16.1 months
Phase 2 N=37 Abiraterone, Radiotherapy and Short-Term Androgen Deprivation in Unfavorable Localized Prostate Cancer
Prostate Cancer
Primary: Percentage of Patients With Undetectable PSA (Prostate-Specific Antigen) at 1 Year — 54.54 percentage of participants
Phase 2 N=41 S1014 Abiraterone Acetate in Treating Patients With Prostate Cancer Who Have Undergone Initial Hormone Therapy
Prostate Cancer
Primary: Number of Patients With Undetectable PSA — 5 Participants
Phase 2 N=138 A Study of IMC-A12 or Ramucirumab Plus Mitoxantrone and Prednisone in Prostate Cancer
Prostate Cancer
Primary: Composite Progression-free Survival (cPFS) — 4.1; 6.7 months
Phase 2 N=28 AZD0530 in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy
Hormone-resistant Prostate Cancer · Recurrent Prostate Cancer
Primary: PSA Response Rate — 0 percentage of participants
Phase 2 N=115 Mitoxantrone ± Cetuximab 2nd Line Androgen Independent Prostate Cancer (AIPC)
Androgen-independent Prostate Cancer
Primary: Median Time to Progression (TTP) — 4.9; 6.6 Months
Phase 3 N=790 Androgen Ablation Therapy With or Without Chemotherapy in Treating Patients With Metastatic Prostate Cancer
Metastatic Hormone-sensitive Prostate Cancer
Primary: Overall Survival — 57.6; 44.0 months — p=0.0003
Phase 2 N=46 A Phase II Study of BAY 43-9006 (Sorafenib) in Metastatic, Androgen-Independent Prostate Cancer
Prostate Cancer
Primary: Progression Free Survival — 1.83; 3.7 months
Phase 2 N=19 Enzalutamide Versus Standard Androgen Deprivation Therapy for the Treatment Hormone Sensitive Prostate Cancer
Adenocarcinoma of the Prostate · Recurrent Prostate Cancer · Stage III Prostate Cancer
Primary: Metabolic Syndrome Incidence, Summarized by the Number of Patients With at Least 3 of the 5 Pre-specified Criteria — 5; 3 Participants — p=0.46
Phase 2 N=118 Neoadjuvant And Adjuvant Abiraterone Acetate + Apalutamide Prostate Cancer Undergoing Prostatectomy
Prostate Cancer
Primary: Combined pCR or MRD Rate [Part 1] — 12; 12 Participants
Phase 4 N=127 Prostate Cancer Study In Men Who Have Failed First-Line Androgen Deprivation Therapy
Neoplasms, Prostate
Primary: Time to Disease Progression — 376.9; 433.1 Days — p=0.79
Phase 2 N=102 Androgen Deprivation Therapy +/- Bevacizumab for PSA Recurrence of Prostate Cancer After Definitive Local Therapy
Prostate Cancer
Primary: Relapse-free Survival — 13; 10 months
Phase 2 N=36 AMG 386 and Abiraterone for Advanced Prostate Cancer
Prostatic Neoplasms · Prostate Cancer · Neoplasm, Prostate
Primary: Progression Free Survival (PFS) — 2.8; 9.0; 11.5; 10.1 Months — p=0.44
Phase 2 N=30 Abiraterone Acetate in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
Hormone-Resistant Prostate Cancer · Metastatic Prostate Carcinoma · Recurrent Prostate Carcinoma
Primary: Change in Tissue Testosterone and Dihydrotestosterone — 0.156 pg/mg
Phase 4 N=206 Study on Enzalutamide and Flutamide in Patients With Castration Resistant Prostate Cancer
Prostate Cancer
Primary: Time to PSA Progression With 1st Line AAT (TTPP1) — 21.39; 5.78 Months — p=<0.001
Phase 2 N=112 Hormone Therapy and Ipilimumab in Treating Patients With Advanced Prostate Cancer
Prostate Adenocarcinoma · Prostate Carcinoma · Recurrent Prostate Carcinoma
Primary: Number of Participants Progression-free at 18 Months — 0 participants
Phase 2 N=41 Study With IMC-A12 (Cixutumumab) in Patients Who Have Not Previously Been Treated With Chemotherapy With Metastatic Prostate Cancer
Adenocarcinoma of the Prostate
Primary: Composite Time to Disease Progression (cTTP) for Participants Treated With Cixutumumab — 4.9; 3.2 months
Phase 2 N=71 Orteronel as Monotherapy in Patients With Metastatic Breast Cancer (MBC) That Expresses the Androgen Receptor (AR)
Metastatic Breast Cancer
Primary: Response Rate (RR) — 4.8; 0 percentage of participants